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Abstract
Background: Congenital cytomegalovirus (CMV) infection is the most common congenital viral infection
in humans and the major nonhereditary cause of central nervous system (CNS) developmental disorders.
Previous attempts to develop a murine CMV (MCMV) model of natural congenital human CMV (HCMV)
infection have failed because MCMV does not cross the placenta in immunocompetent mice.
Results:  In marked contrast with immunocompetent mice, C.B-17 SCID (severe combined
immunodeficient) mice were found to be highly susceptible to natural MCMV transplacental transmission
and congenital infection. Timed-pregnant SCID mice were intraperitoneally (IP) injected with MCMV at
embryonic (E) stages E0-E7, and vertical MCMV transmission was evaluated using nested polymerase chain
reaction (nPCR), in situ hybridization (ISH) and immunohistochemical (IHC) assays. SCID mouse dams IP
injected at E0 with 102 PFU of MCMV died or resorbed their fetuses by E18. Viable fetuses collected at
E18 from SCID mice IP injected with 102–104 PFU of MCMV at E7 did not demonstrate vertical MCMV
transmission. Notably, transplacental MCMV transmission was confirmed in E18 fetuses from SCID mice
IP injected with 103 PFU of MCMV at stages E3-E5. The maximum rate of transplacental MCMV
transmission (53%) at E18 occurred when SCID mouse dams were IP injected with 103 PFU of MCMV at
E4. Congenital infection was confirmed by IHC immunostaining of MCMV antigens in 26% of the MCMV
nPCR positive E18 fetuses. Transplacental MCMV transmission was associated with intrauterine growth
retardation and microcephaly. Additionally, E18 fetuses with MCMV nPCR positive brains had cerebral
interleukin-1α (IL-1α) expression significantly upregulated and cerebral IL-1 receptor II (IL-1RII)
transcription significantly downregulated. However, MCMV-induced changes in cerebral cytokine
expression were not associated with any histological signs of MCMV infection or inflammation in the brain.
Conclusion: Severe T- and B-cell immunodeficiencies in SCID mice significantly enhance the rate of
natural MCMV transplacental transmission and congenital infection. During gestation MCMV exhibits a
tissue tropism for the developing brain, and vertical MCMV transmission is correlated with fetal growth
retardation and abnormal cerebral proinflammatory cytokine expression. These data confirm that natural
vertical MCMV infection in SCID mice constitutes a useful new experimental rodent model of congenital
HCMV infection.
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Background
Cytomegalovirus (CMV), a double-stranded DNA β-her-
pesvirus, is the most common cause of human congenital
infection, with a prevalence rate of approximately 1% for
all live births in the United States (worldwide range 0.5–
2.4%) [1]. CMV is also the leading viral cause of disease
morbidity and mortality in congenitally infected fetuses
and premature neonates [2]. While the majority of con-
genital human CMV (HCMV) infections are asympto-
matic, it has been estimated that 5–10% of HCMV
congenitally infected neonates exhibit symptomatic, gen-
eralized cytomegalic inclusion disease (CID) [3]. Typical
clinical features of CID include petechiae, hepat-
osplenomegaly, jaundice and microcephaly [4]. Addi-
tional manifestations of CID at birth include intrauterine
growth retardation (IUGR), prematurity, chorioretinitis,
and central nervous system (CNS) diseases such as intrac-
ranial calcifications, ventriculomegaly, lissencephaly,
pachygyria, dysmyelination, paraventricular cysts and cal-
cifications [5,6]. Up to 25% of neonates with CID die
from disease complications, and more than 90% of survi-
vors experience significant and permanent CNS and sen-
sory impairments, including intellectual, motor, auditory
and visual system deficits [4,7-9]. Notably, 90% of con-
genital HCMV infected neonates are asymptomatic at
birth, but later in life develop significant sensory system
disorders. The most prevalent delayed-onset sensory sys-
tem sequelae of congenital HCMV infection is sen-
sorineural hearing loss (SNHL), and at least 25% of
children with congenital CMV-induced auditory deficits
develop their hearing losses only after the first year of life
[10-13]. It has been estimated that the direct and indirect
costs for treating the sequelae of congenital HCMV infec-
tions exceeds $1.9 billion per year [14].
The pathogenesis of congenital HCMV-induced nervous
system pathologies is still poorly understood. Because
CMV exhibits strict species-specificity [2,15], it has not
been possible to use HCMV to create experimental animal
models of congenital HCMV infection. Experimental
models of natural, transplacental congenital CMV infec-
tion have been developed in immunocompetent animals
using species-appropriate guinea pig CMV (GPCMV) [16-
26], rat CMV [27], pig [28] and rhesus macaque monkey
CMV (RhCMV) [29,30]. Unfortunately, none of these ani-
mal models have been shown to induce the CNS and sen-
sory system infections and pathologies observed in
congenital HCMV infections [31].
Although immunocompetent mice are highly resistant to
transplacental congenital MCMV infection [31,32], it has
been reported that transplacental passage of lactate dehy-
drogenase-elevating virus (LDEV) was significantly
enhanced in severe T- and B-cell immunodeficient SCID
(severe combined immunodeficient) mice [33]. Conse-
quently, we hypothesized that SCID mice might also be
more vulnerable to transplacental MCMV transmission.
Our results confirmed that pregnant SCID mice are highly
susceptible to natural MCMV vertical transmission and
congenital infection, and that MCMV transmitted across
the placenta exhibits tissue tropisms for the developing
fetal brain and viscera.
Results
Development of a SCID mouse model of congenital 
MCMV infection
SCID mice are extremely susceptible to MCMV infection,
and even 1 PFU of MCMV will eventually kill these
severely T- and B-cell immunodeficient animals [34]. The
initial phase of this experiment consisted of a dose-mor-
tality study conducted to test the susceptibility of SCID
mice to congenital MCMV infection, and to establish an
optimal experimental parameters for this model. SCID
mouse dams were intraperitoneal (IP) injected with 102–
104 PFU of MCMV at developmental ages ranging from
E0-E7, and then allowed to survive until stage E18 of the
normal mouse 20 day gestational period. As shown in
Table 1, none of the SCID mouse dams injected with 102
PFU of MCMV at E0 (N = 4) lived and sustained live
fetuses at stage E18. In contrast, the majority of the SCID
dams inoculated with 103 PFU of MCMV at E3-E7 lived
and maintained live litters at stage E18. Notably, vertical
transmission of MCMV was confirmed by nPCR amplifi-
cation of MCMV immediate-early-gene-1 in live fetuses
collected from SCID mouse dams inoculated with 103
PFU of MCMV at E3 (33%), E4 (100%) and E5 (25%), but
not from dams similarly injected at E7 (0%) (Table 1).
Given that all of the SCID mouse dams IP injected with
MCMV at E3-E7 exhibited significant clinical signs of
MCMV viremia at E18 (e.g., ruffled fur, weight loss,
hunched posture, labored breathing and lethargy), nPCR
negative littermates constituted an experimental control
group which confirmed that fetal brains and abdominal
viscera samples were not contaminated during tissue col-
lection by maternal blood. Based on our findings that the
maximum rate of fetal survival and transplacental MCMV
transmission at E18 was obtained when SCID mouse
dams were inoculated with 103 PFU of MCMV at develop-
mental stage E4, we selected this experimental protocol
for our subsequent studies.
Kinetics of MCMV transplacental transmission
We next investigated the kinetics of vertical MCMV trans-
mission during gestation. SCID dams were IP injected
with either uninfected salivary gland suspension (USGS)
or 103 PFU of MCMV at developmental stage E4, and the
fetuses collected at stages E12, E14, E16 or E18. None of
the USGS control fetuses had MCMV DNA amplified by
nPCR in their brains or viscera (Table 2). In marked con-
trast, MCMV DNA was detected by nPCR (Figure 1A) inVirology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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fetuses at all of the postinfection stages examined (Table
3). Beginning as early as stage E12 (i.e., 8 days postinfec-
tion), MCMV DNA was amplified by nPCR in 38% of the
fetuses (i.e., the whole body was assayed at E12 due to the
small size of the fetus). By stage E14, the youngest gesta-
tional age at which the brains and viscera were examined
separately, 21% of the fetuses had MCMV nPCR positive
brains, and 50% amplified MCMV DNA in either their
brains or viscera. The rate of CMV vertical transmission in
the brain or viscera at stage E16 was 25%, and at E18 the
incidence of transplacental MCMV transmission in
reached a maximum of 53%. Thus, beginning as early as
the end of the second trimester of pregnancy (i.e., E14),
fetal SCID mouse brains and viscera were both major tar-
gets for vertical MCMV transmission.
Congenital MCMV infection and developmental pathology
The incidence of fetal demise was similar for both the
USGS and MCMV groups (Table 4). Embryonic death in
utero typically resulted in rapid resorption of the concep-
tus. Since dead fetuses were macerated or partially
resorbed at the time of maternal sacrifice, fetal remnants
were examined only grossly. However, none of the USGS
control fetuses that were alive, dead or partially reab-
sorbed at stages E12-E18 exhibited any signs of craniofa-
cial maldevelopment.
Primary maternal IP inoculation with 103 PFU of MCMV
at stage E4 did not adversely impact either litter size or the
total number of remnants per litter (Table 4). However,
maternal MCMV inoculation was associated with signifi-
cant reductions in both the size and weight of the surviv-
ing fetuses. When compared to age-matched USGS
controls, the live fetuses with MCMV DNA amplified in
their brains and/or viscera exhibited significant reduc-
tions in their crown-rump length at E12, weight at E14,
and both length and weight at E16 and E18, (Table 4; p <
0.05 or p < 0.01, Student's t-tests). While vertical transmis-
sion of MCMV was associated with whole body intrauter-
ine growth retardation, none of the fetuses that amplified
MCMV DNA exhibited any gross deformities (e.g., cranio-
facial dysmorphic features). Of note, in addition to signif-
icant reductions in body length and weight, the fetuses
with nPCR amplified MCMV DNA also exhibited abnor-
mally small head size (i.e., microcephaly). However,
detailed measurements of head size were not taken at the
time of sacrifice due to experimental time constraints:
after the fetuses were decapitated, within 30 seconds their
Table 1: Transplacental MCMV transmission at E18 following intraperitoneal injection of SCID mouse dams.
SCID DAM PFU of MCMV MCMV Injection Stage Litter Size nPCR Positive Fetusesa
11 0 2 E0 * NA
21 0 2 E0 * NA
31 0 2 E0 * NA
41 0 2 E0 NP NA
51 0 3 E3 * NA
61 0 3 E3 * NA
71 0 3 E3 NP NA
81 0 3 E3 NP NA
91 0 3 E3 5 1
10 103 E3 6 1
11 103 E4 6 1
12 103 E4 4 4
13 103 E4 3 2
14 103 E4 8 1
15 103 E5 NP NA
16 103 E5 7 0
17 103 E5 6 0
18 103 E5 6 4
19 102 E7 NP NA
20 102 E7 7 0
21 102 E7 5 0
22 103 E7 6 0
23 104 E7 NP NA
24 104 E7 NP NA
25 104 E7 NP NA
26 104 E7 NP NA
a: nPCR MCMV DNA positive viscera; brains not tested
*: Dam died prior to E18
NA: Not applicable
NP: Not pregnant with live fetuses at E18Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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heads were bisected sagittally, and the right half-brains
extracted from the skull and snap-frozen in liquid nitro-
gen for cytokine RNase protection assays (see below).
MCMV immunohistochemistry and in situ hybridization
In order to verify transplacental MCMV transmission at
the cellular level, the placentas with attached extraembry-
onic membranes (Figure 2A) and the left half-heads from
the 50 stage E18 fetuses that amplified MCMV DNA in
their right half-brains or viscera were examined by immu-
nohistochemistry (IHC; N = 50) to localize MCMV anti-
gens, and a random sample of the 50 MCMV nPCR
positive fetuses were evaluated by in situ hybridization
(ISH; N = 31) to establish sites of MCMV RNA and DNA
expression. MCMV was not detected by IHC or ISH in any
of the USGS control E18 fetuses, or any of the left half-
heads of the E18 fetuses tested that had nPCR confirmed
vertical MCMV transmission. However, congenital infec-
tion was verified by IHC detection of MCMV antigens in
26% (13/50) of the fetal placentas and extraembryonic
membranes from E18 fetuses that had MCMV DNA
amplified by nPCR in their brains and/or viscera. In addi-
tion, MCMV RNA and DNA were identified in the placen-
tas and extraembryonic membranes of 32% (10/31) of
the MCMV nPCR positive fetuses tested. MCMV antigens
(IHC: Figure 2B), and RNA and DNA (ISH: Figure 2C)
were localized primarily within the fetal visceral splanch-
nopleuric yolk sac membranes and, less frequently, within
the labyrinthine and spongiotrophoblast layers of the
fetal placental disk. Double-label immunostaining con-
firmed congenital MCMV infection in blood vessel
endothelial cells (anti-CD31, Figure 2D) and macro-
phages (i.e., Hofbauer cells; anti-F4/80, Figure 2E) within
the mesodermal layers of the visceral yolk sac.
Cerebral proinflammatory cytokine and cytokine receptor 
expression
RNase protection assays were used to simultaneously eval-
uate the mRNA expression patterns for ten cytokines and
six cytokine receptors (e.g., Figure 1B and 1C) in the
brains of E18 control USGS (N = 28) and experimental
MCMV (N = 45) group fetuses collected from SCID mouse
dams IP injected at stage E4 with 103 PFU of MCMV. The
MCMV group fetuses were divided into three subgroups
based on their MCMV nPCR assay results: brain-/viscera-
(N = 23), brain-/viscera+ (N = 16) and brain+/viscera+ (all
brain+ fetuses were also viscera+; N = 6). The cytokines
tumor necrosis factor-α (TNFα), transforming growth fac-
tor (TGF)-β1, TGF-β2, TGF-β3, interferon-γ (IFNγ), inter-
leukin-1β (IL-1β), IL-1Ra, IL-12p35 and IL-12p40, as well
as the cytokine receptors IL-1RI, IL-12Rβ1, IL-12Rβ2,
IFNγ-Rα, IFNγ-Rβ all had similar expression levels in the
brains of the USGS controls, and the experimental MCMV
nPCR brain-/viscera- and brain-/viscera+ fetuses (all p >
0.10, Mann-Whitney U tests). In marked contrast, when
compared with the control USGS group fetuses, the nPCR
MCMV brain+/viscera+  subgroup exhibited significant
upregulation of cerebral IL-1α mRNA expression and sig-
nificant downregulation of IL-1RII mRNA transcription
(Figure 3; all p < 0.01, Mann-Whitney U test). Notably,
neither the MCMV nPCR brain-/viscera- nor the brain-/vis-
cera+ E18 subgroups demonstrated the same significant
modulation of IL-1α and IL-1RII mRNA expression levels
observed in the MCMV nPCR brain+/viscera+ fetuses. The
fact that the littermates of the E18 nPCR MCMV brain+/
viscera+  subgroup did not exhibit abnormal cerebral
cytokine and cytokine receptor expression levels con-
firmed that the observed brain cytokine effects were
related to transplacental transmission of MCMV in the
fetal brain, and could not be explained by contamination
of the fetus with maternal blood during specimen collec-
tion or by indirect effects secondary to maternal MCMV
infection.
Discussion
Immunodeficiencies, either innate [35,36] or acquired
[37-39], are known to be detrimental to the outcome of
viral infections. Notably, while immunocompetent mice
are highly resistant to congenital MCMV infection
[31,32], the severely T- and B-cell immunodeficient SCID
mice used in this study were found to be highly suscepti-
ble to natural vertical MCMV transmission and congenital
infection. Thus, during gestation the maternal immune
Table 2: MCMV nPCR for fetuses from SCID mouse dams injected with USGS at E4.
USGS Litters
SCID DAM Litters Positive/
Total Litters
Brain+/
Brains Tested
Viscera+/
Viscera Tested
Brain+ or Viscera+/
Fetuses Tested
E12 0/4(0%) * * 0/32(0%)
E14 0/5(0%) 0/32(0%) 0/32(0%) 0/32(0%)
E16 0/6(0%) 0/19(0%) 0/19(0%) 0/19(0%)
E18 0/18(0%) 0/75(0%) 0/75(0%) 0/75(0%)
*: Whole body nPCR assayed to detect MCMV DNA at E12 due to the small size of the fetus.Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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Nested polymerase chain reaction (nPCR) and RNase protection assays (RPAs) Figure 1
Nested polymerase chain reaction (nPCR) and RNase protection assays (RPAs). A: Representative autoradio-
graphs of liquid hybridizations run 2X following nested polymerase chain reaction (nPCR) assays for MCMV immediate-early 
gene 1 (Eco RI E) DNA in the viscera of E18 embryos from a C.B-17 SCID mouse injected with 103 PFU of MCMV at E4. Four 
embryos [lanes A-D] demonstrated MCMV amplification; the fifth fetus [lane E] was MCMV DNA negative. Negative control 
lanes contained AE elution buffer (see text). MCMV control lanes contained AE elution buffer and 250 ag-250 fg of MCMV 
DNA Eco RI E. Note that nPCRs exhibited saturation for the positive controls. B-C: Representative cytokine RPAs for the 
brains of E18 fetuses following maternal IP injection at E4 with uninfected salivary gland suspension (USGS) or 103 PFU of 
MCMV (MCMV). In each lane 10 μg of total brain mRNA from a single E18 fetus was hybridized with one of two probe sets 
designed to detect 10 proinflammatory cytokines and 6 corresponding cytokine receptor transcripts, as well as mL32 and 
GAPDH housekeeping controls (see text). Labeled probe sets were used as size markers in the right lane of each film.Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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system clearly plays a major role in controlling transpla-
cental transmission of MCMV.
Previously, it has been hypothesized that distinctive ana-
tomical features of the mouse placenta might contribute,
in some fashion, to the obstruction of transplacental
MCMV transmission [32]. Notably, the anatomy of the
rodent placenta differs in a number of respects from that
found in other mammalian orders. In particular, the struc-
ture of the trophoblastic layers of the murine chorioallan-
Table 3: MCMV nPCR for fetuses from SCID dams injected with 103 PFU of MCMV at E4.
E12 MCMV Litters
SCID DAM Litter Size Negative Fetuses 
(Brain-/Viscera-)
Positive Fetuses
 (Brain+ or Viscera+)
Brain+ Fetuses 
(Brain+ or Viscera+)a
1 4 4 (100%) 0 (0%) *
2 7 7 (100%) 0 (0%) *
5 4 4 (100%) 0 (0%) *
49 2  ( 2 2 % ) 7  ( 7 8 % ) *
55 1  ( 2 0 % ) 4  ( 8 0 % ) *
Total 29 18 (62%) 11 (38%) *
E14 MCMV Litters
1 4 3 (75%) 1 (25%) 1 (25%)
2 3 0 (0%) 3 (100%) 1 (33%)
3 2 1 (50%) 1 (50%) 0 (0%)
4 8 2 (25%) 6 (75%) 3 (38%)
5 7 6 (86%) 1 (14%) 0 (0%)
Total 24 12 (50%) 12 (50%) 5 (21%)
E16 MCMV Litters
1 5 4 (80%) 1 (20%) 1 (20%)
2 6 1 (16%) 5 (84%) 2 (33%)
3 6 5 (83%) 1 (17%) 0 (0%)
4 7 7 (100%) 0 (0%) 0 (0%)
5 4 4 (100%) 0 (0%) 0 (0%)
6 4 3 (75%) 1 (25%) 0 (0%)
Total 32 24 (75%) 8 (25%) 3 (10%)
E18 MCMV Litters
1 8 7 (86%) 1 (14%) 0 (0%)
2 3 0 (0%) 3 (100%) 3 (100%)
3 5 0 (0%) 5 (100%) 3 (60%)
4 7 4 (57%) 3 (43%) 0 (0%)
5 7 2 (29%) 5 (71%) 1 (14%)
6 3 1 (33%) 2 (67%) 0 (0%)
7 5 3 (60%) 2 (40%) 1 (20%)
8 5 3 (60%) 2 (40%) 1 (20%)
9 3 0 (0%) 3 (100%) 1 (33%)
10 5 3 (60%) 2 (40%) 0 (0%)
11 5 2 (40%) 3 (60%) 0 (0%)
12 3 2 (67%) 1 (33%) 0 (0%)
13 10 7 (70%) 3 (30%) 0 (0%)
14 9 0 (0%) 9 (100%) 5 (56%)
15 10 7 (70%) 3 (30%) 0 (0%)
16 6 3 (50%) 3 (50%) 1 (17%)
Total 94 44 (47%) 50 (53%) 16 (17%)
*: Whole body nPCR assayed to detect MCMV DNA at E12 due to the small size of the fetus.
a: All nPCR brain+ fetuses were also nPCR viscera+.Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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toic placenta is exceptional in that maternal blood is
separated from fetal blood by three (hemotrichorial) tro-
phoblast layers, a basement membrane, and a layer of
fetal vascular endothelial cells. In comparison, in
humans, guinea pigs and monkeys the placenta contains
only a single trophoblast (monochorial) layer [32]. Thus,
the two extra layers of trophoblastic cells between the
maternal and fetal blood in mice could provide a physical
barrier which serves to limit the vertical transfer of MCMV
from the mother to the conceptus. However, since no ana-
tomical differences between the placentas of SCID mice
and congenic immunocompetent mice have been identi-
fied, and given our findings that SCID mice are highly sus-
ceptible to transplacental MCMV transmission,
presumably there is some alternative mechanism, not
based on the anatomy, which limits vertical MCMV trans-
mission in immunocompetent mice. Possible candidates
for an impediment to transplacental viral passage other
than a physical "barrier" could include the local produc-
tion of protective cytokines, the generation of intrinsic
antibody, and the lack of expression of specialized cell
surface receptors required for MCMV attachment and pen-
etration of cells on one, or more, of the trophoblast layers
[32]. However, whatever the barrier to transplacental virus
passage in immunocompetent mice turns out to be, once
it has been breached the conceptus is clearly susceptible to
congenital MCMV infection [40-43].
In humans and many other mammals the fetal placenta is
reportedly the initial site of congenital CMV infection [44-
47]. Consequently, Fisher et al. [44] hypothesized that
infection of the placenta is a necessary prerequisite for the
development of congenital CMV infection in the fetus.
Since human placental trophoblasts are permissive for
HCMV infection in vitro and in utero [44], and given that
both murine and human placentas contain similar fetal
cell elements [32], we anticipated finding MCMV infec-
tion in the placentas of all of the fetuses that had vertical
MCMV transmission. Instead, MCMV transcription (ISH)
and translation (IHC) was detected in only 26% of the
placentas and extraembryonic membranes from E18
fetuses with MCMV nPCR positive brains or viscera. How-
ever, nPCR is a more sensitive technique than IHC and
ISH assays. Thus, it is possible that additional fetal placen-
tas in this study were in fact infected with MCMV, but that
the viral loads in these tissues were below the threshold of
detection of our IHC and ISH assays. Alternatively, verti-
cal MCMV transmission may have occurred without infec-
tion of the placenta, an attractive possibility given
evidence that HCMV is frequently transmitted from
Table 4: Development of C.B-17 SCID mouse fetusesa.
USGS Litters
Embryonic Stage Number Litters Number Fetusesb Number Remnantsc Body Weight
(Mean ± SE)
Crown-Rump Length
(Mean ± SE)
E12 4 32 3 0.07 g ± 0.01 8.51 mm ± 0.23
E14 5 32 5 0.20 g ± 0.01 11.04 mm ± 0.11
E16 6 19 8 0.78 g ± 0.06 17.25 mm ± 0.77
E18 18 75 15 1.00 g ± 0.03 19.08 mm ± 0.28
MCMV Litters
Embryonic Stage Number Litters Number Fetusesb Number Remnantsc Body Weight
(Mean ± SE)
Crown-Rump Length
(Mean ± SE)
E12 5 29 (11)d 7 0.07 g ± 0.01
(0.05 g ± 0.01)d
8.14 mm ± 0.24
(6.65 mm ± 0.41)d*
E14 5 24 (12) 10 0.18 g ± 0.01*
(0.17 g ± 0.02)*
10.61 mm ± 0.20
(10.46 mm ± 0.37)
E16 6 32 (8) 9 0.51 g ± 0.02**
(0.52 g ± 0.03)*
14.42 mm ± 0.23**
(14.06 mm ± 0.38)*
E18 16 94 (50) 16 0.82 g ± 0.02**
(0.81 g ± 0.02)*
18.05 mm ± 0.19**
(18.18 mm ± 0.28)**
a: SCID mouse dams were intraperitoneally injected with either USGS or 103 PFU of MCMV at E4, and live fetuses were collected at the indicated 
embryonic (E) stages.
b: Live fetuses pooled across litters.
c: Dead/reabsorbed fetuses pooled across litters.
d: (fetuses nPCR MCMV DNA positive in brains and/or viscera).
Statistical significance levels (USGS vs. MCMV): * p < 0.05, ** p < 0.01, Student's t-tests.Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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Congenital MCMV infection in E18 fetal membranes Figure 2
Congenital MCMV infection in E18 fetal membranes. Pregnant SCID mice were injected with 103 PFU of MCMV at E4. 
A: H&E staining of an E18 SCID mouse placenta with extraembryonic membranes. ST, spongiotrophoblastic zone; LT, labyrin-
thine zone; visceral yolk sac in box. B: Anti-MCMV immunostaining (green; arrow) for viral antigens in the mesodermal layer of 
the visceral yolk sac boxed in (A). C: In situ hybridization (purple; arrow) for MCMV RNA in the mesodermal layer of the vis-
ceral yolk sac boxed in (A). D: Anti-MCMV immunostaining (green) in endothelial cells (anti-CD31+: red) in the walls of blood 
vessels (arrows) within the visceral yolk sac of an E18 embryo. E: Anti-MCMV immunostaining (green, arrows) within macro-
phages (anti-F4/80: red) in the visceral yolk sac mesoderm of an E18 embryo. A,D&E: Bisbenzimide nuclear stain (blue). A: Bar 
= 1 mm; B&C: Bars = 100 μm, D&E: Bars = 20 μm.Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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Effects of congenital MCMV infection on cerebral IL-1α and IL-1RII transcription Figure 3
Effects of congenital MCMV infection on cerebral IL-1α and IL-1RII transcription. Densitometric analyses of (A) IL-
1α and (B) IL-1RII mRNA expression in the brain. Pregnant SCID mice were injected at E4 with USGS or 103 PFU of MCMV 
and the fetuses collected at stage E18. MCMV DNA-positive fetuses were divided into three nPCR subgroups: fetuses that did 
not amplify MCMV DNA in either the viscera or brain (brain-/viscera-); fetuses with MCMV DNA amplified in the viscera but 
not the brain (brain-/viscera+); and fetuses with MCMV DNA amplified in the brain and viscera (brain+/viscera+). Autoradio-
graphs were scanned using GelPro 3.0 software to generate maximum optical density (MOD) values, and IL-1α and IL-1RII 
transcript levels were normalized [(mRNA transcript)/mL32] for comparisons between autoradiographs. Statistical significance 
of USGS vs. MCMV nPCR subgroup comparisons: ** p < 0.01, Mann-Whitney U tests.Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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mother to fetus by transcytosis across the syncytium with-
out infection of syncytiotrophoblasts [44]. The level of
MCMV viremia in the dams was not examined in this
study, and future experiments are required to determine
the extent to which transplacental MCMV transmission is
dependent upon the maternal viral load.
Once transplacental MCMV transmission occurred, the
fetal brain and visceral organs became prominent targets
for congenital infection in SCID mice. However, the
extent of intrauterine growth retardation for the fetuses
with nPCR confirmed vertical MCMV transmission was
not significantly different from their MCMV nPCR nega-
tive littermates (Table 4). This suggests that MCMV-
induced changes in the placenta, and not direct effects of
the virus on the fetus, were the primary cause of the fetal
growth and developmental delays observed in the MCMV
experimental groups. Since MCMV infection is known to
degrade the normal tight attachments between cells in
vitro and in vivo [48,49], it is possible that MCMV-induced
degradation of the attachments between syncytiotrophob-
lasts and cytotrophoblasts in the syncytiotrophoblast lay-
ers of the placenta interfered with the normal exchange of
nutrients, gasses, wastes, etc. across the maternal-fetal
interface during pregnancy. Alternatively, a break-down in
the attachments between syncytiotrophoblasts and
cytotrophoblasts may have created channels through
which cell-free virus could be transmitted from mother-
to-fetus. While we did not detect any histopathological
signs of placental hemorrhage, MCMV-infected endothe-
lial cells were frequently observed in visceral yolk sac
blood vessels (e.g., Figure 2D), findings which suggest
that viral infection may have compromised the integrity
of the maternal-fetal blood barriers. Histological evidence
that congenital viral infection can induce placental
pathology has been provided by Amedee et al. [50], who
reported that infarcts were common at the basal plate of
the placenta for rhesus macaque monkeys that developed
congenital simian immunodeficiency virus (SIV) infec-
tions, and that these vascular ruptures were large enough
to permit viral passage across the maternal-fetal barrier.
Another mechanism that could contribute to vertical
MCMV transmission in SCID mice would be the transpla-
cental passage of infected inflammatory cells. Since CMV
is a macrophage-tropic virus [51], it has long been sus-
pected that infected macrophages may serve as a "Trojan
horse" that could convey the virus from mother-to-fetus
across the placenta [50,51]. Evidence supporting a macro-
phage-based transplacental transport mechanism has
been reported by Amedee et al. [50], who found signifi-
cant reservoirs of macrophages on the maternal side of the
basal placental plate, and high concentrations of Hof-
bauer cells (i.e., fetal macrophages) on the fetal side of the
placenta in rhesus macaque monkeys that developed con-
genital SIV infections. The current study also detected high
concentrations of MCMV-infected Hofbauer cells on the
fetal side of the placenta in congenitally infected SCID
mice (Figure 2E). Thus, our data are consistent with the
hypothesis that maternal immunodeficiency may pro-
mote transplacental transmission of MCMV, either as free
virus or contained within infected maternal macrophages,
and that the virus is subsequently amplified in fetal Hof-
bauer cells.
The clinical correlates of transplacental MCMV transmis-
sion in SCID mice closely resembled those reported in
congenital HCMV studies. Consistent with the very low
rate (<0.10%) of symptomatic congenital HCMV infec-
tion in human neonates [2,3,7], we did not observe any
examples where primary MCMV infection of SCID mice
during pregnancy induced cytomegalic inclusion disease
(CID) or any gross dysmorphic features in the fetuses.
However, MCMV that crossed the placenta did exhibit a
tissue tropism for the fetal SCID mouse brain, a finding in
agreement with earlier clinical reports that congenital
HCMV infection targets the developing brain [2,3,7] and
is the leading infectious cause of human congenital CNS
pathology [52-54]. Notably, in earlier experimental stud-
ies, the induction of congenital MCMV by direct inocula-
tion of the fetus in utero with high-dose MCMV was found
to cause CNS infection, neuronal apoptosis and gross
craniofacial deformities in immunocompetent mice [40-
43]. Thus, the absence of any signs of gross craniofacial or
CNS malformations in the present study was not consist-
ent with the previously reported congenital MCMV infec-
tion studies. The discrepancies between the current study
and the prior investigations may be explained by the fact
that direct injection of the fetus in utero with high-dose
MCMV presumably produced significantly higher fetal
viral loads than those attained by natural transplacental
congenital MCMV infection in SCID mice. Consistent
with the viral load hypothesis, we have observed in ongo-
ing studies that direct injection of SCID mouse fetuses in
utero at E11 with 68 PFU of MCMV also can induce con-
genital MCMV infection and neuropathology in the devel-
oping CNS (unpublished observations).
While there is an extensive literature on cerebral cytokine
expression and function during viral infections of the
brain in mature subjects [55], to our knowledge this was
the first in vivo study to investigate the effects of transpla-
cental CMV transmission on cerebral cytokine transcrip-
tion. Most cytokines are expressed at low or undetectable
levels in the healthy adult brain, but many are induced or
modulated by CNS infections [56]. One of the most
widely studied proinflammatory cytokines in the brain is
IL-1. The IL-1 family is comprised of at least three pro-
teins, the best characterized of which are IL-1α, IL-1β and
IL-1 receptor antagonist (IL-1Ra). IL-1α and IL-1β are bio-Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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active agonists, and IL-1Ra is thought to function as an
endogenous receptor antagonist [56]. The biological
actions of IL-1 family members are mediated by binding
to two distinct forms of receptors: a biologically active
type I receptor (IL-1RI) and a presumed decoy receptor IL-
1RII [57]. With respect to viral infection, experimental evi-
dence suggests that the IL-1 family plays a pivotal role in
MCMV pathogenesis and the reactivation of latent virus in
adult mice [58], and that IL-1 signaling in the CNS elicits
responses which can either exacerbate or inhibit neuronal
cell death (i.e., apoptosis) in neonatal and adult immuno-
competent mice [59-61].
Notably, the E18 fetuses in this study with nPCR con-
firmed vertical MCMV transmission in the brain also
exhibited abnormal cerebral IL-1 expression levels: IL-1α
mRNA transcription was significantly upregulated and IL-
1RII mRNA expression was significantly downregulated.
Since IL-1α functions as an agonist and IL-RII reportedly
acts as a decoy receptor that traps free IL-1α [56], the com-
bination of increased IL-1α expression and decreased IL-
1RII transcription in the brain would result in an overall
net increase the amount of IL-α available for signaling in
the brains of MCMV congenitally infected fetuses. Acting
through a variety of different effects on the developing
CNS, such as the induction of neuronal apoptosis [59-61],
activation of gliosis, growth factors, adhesion molecules,
corticotrophin-releasing factor (CRF), free radicals, and
complement, as well as modulation cellular calcium
homeostasis [56] and neuroendocrine (i.e., hypotha-
lamic-pituitary-adrenal-axis) responses [62,63], an
increase in the level of cerebral IL-1α signaling could
effect the secretion of pituitary growth hormones [64],
and thereby (directly or indirectly) contribute to the fetal
growth retardation that is a characteristic of congenital
HCMV infected humans [45,47] and MCMV infected
SCID mice (this study).
The etiology of the brain pathology and sensory deficits
(e.g., hearing and vision losses) induced by congenital
HCMV infections is still poorly understood, and the
development of a valid experimental animal model
would be advantageous. Due to the species-specificity of
CMV [2,15], it has not been possible to use HCMV in ani-
mal congenital infection models. As an alternative, natu-
rally occurring transplacental viral transmission has been
employed to create models of congenital HCMV infection
in guinea pigs [16-24], rats [27], pigs [28] and rhesus
macaque monkeys [29,30]. The rhesus macaque monkey
model of congenital HCMV infection has been limited by
the animal's prolonged gestation time, the fact that
RhCMV is endemic throughout the available study popu-
lation, as well as general considerations about working
with higher primates [29,30]. To date, the most com-
monly used animal species employed to model congenital
HCMV infections has been the guinea pig, and congenital
GPCMV infection has been utilized extensively in studies
by ourselves [21,22] and many others [16-20,23-26].
However, although guinea pig studies have provided sig-
nificant insights into the cellular and molecular mecha-
nisms underlying congenital GPCMV infection, the
guinea pig congenital infection model is somewhat lim-
ited in that natural vertical GPCMV infection does not
reproduce the CNS neuropathology that has been
described in symptomatic congenital HCMV case reports
[4,7-9]. Notably, a new rat model of natural transplacen-
tal RCMV transmission has recently been described, but
none of the RCMV congenitally infected rat embryos or
neonates reported had infectious virus, viral antigen or
DNA detected in the brain [27].
Although the rate of transplacental MCMV transmission
in this study reached a high of 53% at E18, and up to 21%
of the fetuses collected at developmental stages E12-E18
from MCMV injected SCID mouse dams had MCMV DNA
amplified in their brains, no evidence of fetal cranial
deformity or CNS neuropathology was detected. Thus,
while the SCID mouse model constitutes an important
new experimental approach for investigating the role of
maternal immunity in the development of MCMV trans-
placental transmission and congenital infection, at this
time direct MCMV injection of the mouse fetus in utero
remains the best available method for investigating the
etiopathogenesis of congenital MCMV infection-induced
birth defects [40-42]. However, there is evidence that not
all of the pathologic effects of congenital CMV infection
are evident at birth. Notably, there is clinical evidence that
more than 25% of the children who develop congenital
HCMV-induced sensory system deficits (e.g. hearing loss)
do so only after the first year of life [7,10]. Because mice
are extremely altricial animals, it is not until several weeks
postpartum that maturation of the mouse brain neurosen-
sory systems is comparable to that of humans at birth
[65]. Thus, since that the oldest developmental age exam-
ined in the current study was E18, and given that the
severity of congenital CMV pathologies can increase pro-
gressively with chronological age, it will be of considera-
ble interest to determine in future studies whether MCMV
congenitally infected SCID mice that survive beyond term
birth will go on to develop late-onset sensory system (e.g.,
hearing and vision) deficits and CNS neuropathologies
similar to those that emerge in congenital HCMV disease
[4,7-9].
Conclusion
Natural vertical transmission of MCMV occurred fre-
quently and reproducibly in immunodeficient C.B-17
SCID mouse dams that were infected with MCMV during
the first trimester of pregnancy. Kinetic studies deter-
mined that the maximum rate of MCMV transplacentalVirology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
Page 12 of 16
(page number not for citation purposes)
transmission and congenital infection in E18 fetuses was
obtained when SCID mouse dams were IP injected with
103 PFU of MCMV at embryonic stage E4. MCMV exhib-
ited a tissue tropism for the developing fetal brain and vis-
cera, and transplacental transmission of MCMV DNA into
the fetal brain was associated with significant changes in
the constitutive expression levels of the proinflammatory
cytokine IL-1α and its bioactive IL-1RII receptor in the
CNS. These findings have confirmed that the natural
murine barrier to transplacental MCMV transmission is
compromised in SCID mice, that transplacental MCMV
transmission in SCID mice can induce congenital MCMV
infection, and that the SCID mouse congenital MCMV
infection model can provide a useful new experimental
approach for future studies on the cellular and molecular
mechanisms that regulate MCMV vertical transmission
and viral pathogenesis.
Methods
Animals
Young adult (10–14 week old) specific pathogen-free C.B-
17 SCID mice of both sexes were purchased from Taconic
Farms (Germantown, NY). Animals were housed and
maintained at the San Diego VA Veterinarian Medical
Unit in microisolator cages housed in a clean room with
positive air pressure and filtered air. Food, water, bedding
and cages were routinely autoclaved. MCMV infected ani-
mals were housed separately from uninfected animals.
Experimental protocols were approved by the San Diego
VA Medical Center Animal Welfare Committee, and con-
formed with the PHS "Guide For the Care and Use of Lab-
oratory Animals".
Treatments and tissue preparation
Following established convention, pregnancies were
dated as E0 on the morning of the day a vaginal seminal
plug was found following overnight mating. At the desig-
nated gestational stages (E0-E7), experimental pregnant
SCID mice were injected IP with 102–104 PFU of MCMV
in 0.2 ml of PBS (MCMV group), and control SCID mice
inoculated with a similar volume of USGS diluted in PBS
(USGS group). After post-injection survival to the appro-
priate gestational stage (E12-E18), mothers were deeply
anesthetized [IP injection with 80 mg/kg sodium pento-
barbital (Nembutal) and 5 mg/kg diazepam (Valium)].
All of the surgical instruments used to harvest fetuses and
to dissect tissue samples were treated throughout the pro-
cedure with ELIMINase (Fisher Scientific, Pittsburgh, PA)
to eliminate RNase and DNase contaminants that could
degrade RNA and DNA samples or interfere with subse-
quent enzymatic reactions. Using a Zeiss OPMI-1 operat-
ing microscope, the peritoneal cavity was exposed by a
transabdominal incision, the two horns of the uterus gen-
tly extracted, individual amniotic sacs identified and
opened, and the fetuses and their placentas (with attached
extraembryonic membranes) collected separately. Due to
the small size of the E12 fetuses, the whole body was uti-
lized at this stage for nPCR assay. For E14-E18 fetuses, the
bodies were decapitated, the head bisected, the abdomen
resected, and the abdominal viscera (i.e., the contents of
the peritoneal cavity with the exception of the small intes-
tine) and one half of the brain were processed separately
for nPCR. The remaining half-brain was either snap frozen
and stored at -70°C for RNase Protection Assay (RPA), or
prepared for in situ hybridization (ISH) and immunohis-
tochemistry (IHC) assays. Half-brains and placentas des-
ignated for ISH or IHC were immersion fixed overnight in
5% paraformaldehyde at 4°C [21,66], embedded in either
paraffin or (cryoprotected in 30% sucrose and frozen in)
OCT, sectioned (10 μm), collected onto Biobond (Ted
Pella, Redding, CA) coated Fisher SuperFrost Plus slides
(Fisher Scientific), and air and vacuum dried.
Virus and cell culture
Smith strain MCMV (ATCC #VR-194) was passaged in
Swiss mice. Salivary gland suspensions (10% wt/vol) were
prepared in Hank's Balanced salts and 10% DMSO, aliq-
uoted and stored at -70°C. For control inoculums, unin-
fected salivary gland suspensions (USGS) were prepared
similarly from MCMV-free Swiss mice. MCMV infectivity
was titered on subcultured mouse embryonic fibroblasts
by plaque assay [67]. The titer of the MCMV stock was 3.6
× 106 PFU/ml. A fresh aliquot of stock MCMV was thawed
and diluted for each experiment.
Nested PCR for MCMV
Nested PCR (nPCR) gene amplification was conducted
using two sets of 30-bp oligonucleotide primers (external
and internal) selected from exon 4 of the MCMV immedi-
ate-early gene 1 from published sequence [68] as
described by Collins et al. [69]. DNA was extracted from
brains and viscera using the QiaAmp DNA Kit (Qiagen,
Valencia, CA), as stated by the manufacturer. For the exter-
nal PCR gene amplification reactions, 10 μl of sample
DNA(1–3 μg), 10 μl of negative control AE Elution buffer
(Qiagen), or 10 μl of positive controls [5 μl AE Elution
buffer (Qiagen) plus 5 μl of purified MCMV DNA frag-
ment Eco RI E (250 ag, 2.5 fg, 25 fg, or 250 fg), which con-
tains the immediate-early gene 1 [68, 70]] was added to a
reaction mixture containing a final concentration of 200
μM of each dNTP, 50 pmole of each external primer, 2
mM MgCl2, 1XGeneAmp PCR buffer II (PE Applied Bio-
systems, Foster City, CA), and 2 units AmpliTaq Gold (PE
Applied Biosystems) in a total volume of 100 μl. Reac-
tions were incubated at 94°C for 12 min to activate the
Taq, then amplified in an Ericomp (San Diego, CA) auto-
mated thermal cycler for 35 cycles as follows: denatura-
tion at 95°C for 40 sec, annealing of extension primers at
55°C for 40 sec, and primer extension at 72°C for 1 min,
with a final extension at 72°C for 7 min.Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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For secondary, internal reactions, 5 μl of the primary reac-
tion was added to a reaction mixture of 200 μM of each
dNTP, 50 pmole of each internal primer, 2 mM mgCl2,
1XGeneAmp PCR buffer II (PE Applied Biosystems), and
2 units AmpliTaq Gold (PE Applied Biosystems) in a total
volume of 100 μl. Internal reactions were incubated as in
the external reactions, and amplified for 30 cycles. Ampli-
fied products were analyzed by liquid hybridization: sam-
ple mixtures [10 μl of internal reaction product + 4 ×
105cpm/μl 32P end-labeled oligo probe [69] in a final vol-
ume of 20 μl of 15 mM NaCl + 10 m MEDTA (pH 8.0)]
were incubated at 100°C (5 min) to denature the ampli-
fied product, then incubated at 56°C (10 min) for anneal-
ing of the probe, loaded and run on an 8%
polyacrylamide gel, and then placed under XAR-5 film
(Kodak, Rochester, NY) overnight. Sensitivity of this
nPCR assay was 250 ag of MCMV DNA, which corre-
sponds to 17.5 genomic equivalents.
Multiprobe RNase protection assay (RPA)
Total RNA was isolated from fetal brains and viscera using
Trizol (Invitrogen, Carlsbad, CA), as recommended by the
manufacturer. The integrity of the RNA was analyzed on
agarose gels prior to RPA. RPA was performed using the
RiboQuant Multi-Probe RNase Protection Assay System
(BD PharMingen, San Diego, CA) according to the manu-
facturer's protocol. Two custom-made probe sets (BD
PharMingen) contained DNA-templates for the cytokines
IL-1α, IL-1β, IL-1Ra, IL-12p35, IL-12p40, IFNγ, TNFα,
TGFβ1, TGFβ2, and TGFβ3, and the cytokine receptors IL-
1RI, IL-1RII, IL-12Rβ1, IL-12Rβ2, IFNγRα, and IFNγRβ, as
well as the housekeeping genes GAPDH and mouse large
ribosomal subunit protein 32 (mL32). The DNA template
sets were used to generate [α-32P]UTP-labeled antisense
riboprobes with high specific activity by in vitro transcrip-
tion using T7 polymerase and [α32P]UTP (3000 Ci/10
mCi/ml; In Vitro Transcription Kit, PharMingen) as rec-
ommended by the manufacturer. In brief, 10 μg of total
brain RNA from each sample, Yeast tRNA (negative con-
trol), or 1 μg control RNA (PharMingen), were hybridized
to 2.9 × 105 cpm/μl of labeled probe. The hybridizations
were performed in eppindorf tubes, placed in a metal rack
with a pressure plate (RPI Corp., Mount Prospect, IL) and
submerged in a water bath overnight at 56°C. Samples
were then digested with RNase, treated with proteinase K,
ethanol precipitated and resuspended in 5 μl of loading
buffer (Pharmingen). Protected fragments were purified
and separated on 5% polyacrylamide gels, dried, and put
under XAR-5 film (Kodak) for 3–4 day exposures. The
films were scanned (Hewlett-Packard ScanJet 4C, Palo
Alto, CA), and the resulting bands quantified using Gel
Pro (Media Cybernetics, Silver Spring, MD) Maximum
Optical Density (MOD) settings. For each sample lane,
the intensity of the cytokine and cytokine receptor bands
were normalized by dividing their MOD values by the cor-
responding mL32 housekeeping gene MOD values.
MCMV in situ hybridization (ISH)
In situ hybridization for MCMV mRNA and DNA was con-
ducted with 1 μg of an equimolar mixture of MCMV frag-
ments EcoR1-E, EcoR1-V and EcoR1-P (kindly provided
by Dr. Deborah Spector) which correspond to regions of
the MCMV genome where transcription occurs primarily
at immediate-early, early and late times during infection
respectively [67,70,71], or the vector pACYC (used as a
negative control), were nick translated in the presence of
40 μM dCTP, dATP, dGTP, DIG-11-dUTP, 10 mM DTTP
for 1.5 h using a Invitrogen Nick Translation kit (Invitro-
gen). The reactions were stopped, precipitated and resus-
pended in 100 μl of 10 mM Tris in 1 mM EDTA (pH7.5).
Tissue sections (10 μm), prepared from paraffin [depar-
affinized in Hemo-De (Fisher Scientific, Pittsburgh, PA)
and rehydrated in graded ethanol] or OCT frozen blocks,
were placed in 1×PBS twice for 5 min. For prehybridiza-
tion, sections were placed in 0.2 N HCl at room tempera-
ture for 20 min, dipped in ddH2O, put in 2×SSC at 70°C
for 30 min, dipped in ddH2O, digested in 20 mM Tris
(pH7.4), 2 mM CaCl2, 4 μg/ml proteinase K at 37°C for
30 min, washed in ddH2O at room temperature for 5 min,
dehydrated in graded alcohol's, and then air dried.
Hybridization buffer consisted of 50% de-ionized forma-
mide, 10% dextran sulfate, 0.05% polyvinylpyrolidone,
50 mM Tris-HCL (pH7.4), 300 mM NaCl, 250 μg/ml her-
ring sperm DNA, 500 μg/ml mouse liver RNA, 100 μg/ml
Poly A, and 0.05% SDS. To detect MCMV DNA and mRNA
simultaneously, sections with hybridization buffer were
p u t  a t  9 5 ° C  f o r  6  m i n ,  t h e n  o n  i c e ,  s e a l e d  w i t h  D P X
(Fluka, Milwaukee, WI) and hybridized at 42°C overnight
with either the E, P, and V mixture, or the pACYC (con-
trol) labeled probe (33 pg/μl resuspended in hybridiza-
tion buffer). Sections were then washed sequentially in
2×SSC+0.1% Triton X-100 (1 h at room temperature),
1×SSC+0.1% Triton X-100 (1 h at room temperature),
0.5×SSC+0.1% Triton X-100 (30 min at 37°C),
0.1×SSC+0.1% Triton X-100 (1 h at room temperature),
and finally 1×Washing buffer (100 mM Tris, 150 mM
NaCl pH7.5)+0.5% Triton X-100 (10 min at room tem-
perature. After blocking (2% Roche blocking buffer
(Roche, Indianapolis, IN) in Washing buffer plus 0.5%
Triton X-100; 30 min at room temperature), sections were
incubated with a 1:750 dilution of anti-digoxigenin anti-
body (Roche) in 1% Blocking buffer (2% Roche Blocking
buffer diluted 1:1 with Washing buffer) (2 h at room tem-
perature). Sections were then washed 3× in Washing
buffer containing 0.5% Triton (5 minutes each at room
temperature), followed by an equilibration in Detection
buffer (100 mM Tris, 100 mM NaCl pH9.5), 10 mM
MgCl2, and 240 μg/ml levamisol (2 min at room temper-
ature). To visualize the digoxigenin reaction develop-Virology Journal 2007, 4:26 http://www.virologyj.com/content/4/1/26
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ment, sections were incubated with 0.33 mg/ml NBT, 0.16
mg/ml BCIP in 1×Detection buffer+10 mM MgCl2+240
μg/ml levamisol (overnight at room temperature in the
dark). Development was stopped by washing the slides
2×ddH2O (5 minutes each), and cover slipped with Crys-
talmount (Biomeda Corp., Foster City, CA).
MCMV immunohistochemistry (IHC)
In brief, an enzymatic unmasking of antigenic sites was
performed by treating sections with 0.1% w/v trypsin in
PBS for 30 min at 37°C. Nonspecific binding was blocked
using a M.O.M (Mouse-On-Mouse) kit (Vector Labs, Bur-
lingame, CA) as described by the supplier, incorporating
5% BSA and 0.1% Triton-X100 in PBS in the initial block-
ing step. Sections were then incubated overnight at 4°C
with mouse anti-MCMV (see below) and either rat anti-
F4/80 (anti-macrophage/microglia: Serotec, Raleigh, NC)
or rat anti-CD31 (anti-endothelial cell: Pharmingen, La
Jolla, CA). Subsequently, sections were incubated at room
temperature for 1 h with Alexa Fluortm 488 goat anti-
mouse IgG (Molecular Probes, Eugene, OR), and then 1 h
with Alexa Fluortm  594 goat anti-rat IgG (Molecular
Probes). Control tissues were incubated with normal
mouse IgG (for anti-MCMV) and normal rat IgG (for F4/
80 and CD31), and processed as above.
Anti-MCMV hyperimmune sera was prepared as described
by Inada et al. [72]: Specific Pathogen Free Charles Rivers
CD1 mice were IP injected with 104 PFU of MCMV, fol-
lowed by two further MCMV IP inoculations at 2-week
intervals, and then bled 7 days after the last injection. IgG
Fc fragments were isolated from sera using an Immunop-
ure-G® IgG purification kit (Pierce, Rockford, IL), and pro-
tein concentration determined using a BAC Protein Assay
kit (Pierce).
Photomicroscopy
Images were obtained using a Zeiss Axioplan 2 micro-
scope equipped with fluorescent illumination and fluo-
rescein, Texas Red, and DAPI filter sets. Images were
digitally captured using an KX85 CCD camera (Apogee
Instruments Inc., Tuscon, AZ), and optimized in Image
Pro (Media Cybernetics) or Adobe Photoshop (San Jose,
CA).
Statistical analyses
All data are expressed as the mean ± SE, and differences
between groups were evaluated by Student's t-tests and
Mann-Whitney U tests using SPSS (SPSS Inc., Chicago,
IL), with probability values p < 0.05 considered signifi-
cant.
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